Description
Anticoagulation Market Snapshot
As per CRI’s report, the global anticoagulation market is anticipated to register a healthy CAGR of 7.80% during the review period to surpass USD 31,696.59 million by 2027. Anticoagulants are ordinarily known as blood thinners, which are compound substances that decrease blood coagulation and blood thickening time.
Oral anticoagulants are accessible in different measurements structures, for example, pill or tablet structure and intravenous dose. Moreover, a portion of the anticoagulants is utilized in clinical hardware, for example, test tubes, blood bonding sacks, and dialysis gear. In addition, warfarin was initially supported as an anticoagulant.
The growth of the global anticoagulation market is attributed to the increasing prevalence of cardiovascular and coronary artery diseases, dependence on anticoagulants, and the growing geriatric population.
Many major market players and entrants have various attractive market opportunities due to the growing patient population supporting new product launches. However, stringent regulatory policies are expected to hinder the market growth during the review period.
Anticoagulation Market Segment Overview
The global anticoagulation market has been classified into Direct Oral Anticoagulants (DOACS), Disease Indication, Route of Administration (ROA), a distribution channel.
The direct oral anticoagulants segment has been further classified into Warfarin, another vitamin K, and Low Molecular Weight Heparin (LMWH).
Based on Disease Indication the global market is divided into Heart Attack, Stroke, Deep Vein Thrombosis/ Pulmonary Embolism DVT/PE, Mechanical Heart Valves (MHV).
Based on the Route of Administration (ROA) segment the global market has been segmented into Oral, injectable, and others.
By Distribution Channel the global market has been classified into Retail Pharmacy, Hospital Pharmacies, and Online Pharmacies.
Anticoagulation Market Regional Analysis
North America is likely to hold the greatest piece of the pie during the review time frame.
In North America, the anticoagulation market is driven by an expanding number of heart patients, rising mindfulness about constant and way of life infections, new item dispatches, and the presence of major players. Since medical care consumption is high in North America, anticoagulation is broadly used to lessen cluster arrangement, prompting the danger of coronary illness.
Asia-Pacific is expected to enroll the most elevated development rate during the figure time frame from 2020 to 2027. This is because of variables such as an expanding predominance of constant illness, enormous populace base, ascent in geriatric populace, rising discretionary cash flow, and increasing fabricating offices of vital participants.
Europe represented a market size of USD 5,205.37million in 2019 and is relied upon to show a CAGR of 7.26% during the gauge time frame. The market development is licensed to the ascent in research & development activities, expanded commonness of ongoing heart sicknesses, and an ascent sought after for cutting edge therapeutics.
Major Companies Covered
The key players of the global anticoagulation market are Pfizer Inc (US), Novartis AG (Switzerland), Sanofi (France), GlaxoSmithKline plc (UK), Daiichi Sankyo Company, Limited (Japan), Johnson & Johnson Services Inc (US), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (US), Hoffmann-La Roche Ltd (Switzerland), and Portola Pharmaceuticals, Inc (US).
COVID 19 Impacts on Anticoagulation Market
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.
Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Global Leukemia Therapeutics Market 2029
Table of Contents
LIST OF CONTENTS
1 EXECUTIVE SUMMARY 14
2 MARKET INTRODUCTION 15
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.3 RESEARCH OBJECTIVE 15
2.4 MARKET STRUCTURE 15
2.5 ASSUMPTIONS & LIMITATIONS 16
3 RESEARCH METHODOLOGY 17
3.1 DATA MINING 17
3.2 SECONDARY RESEARCH 18
3.3 PRIMARY RESEARCH 18
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING TECHNIQUES 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 22
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 23
3.8 VALIDATION 23
4 MARKET DYNAMICS 24
4.1 OVERVIEW 24
4.2 DRIVERS 25
4.2.1 RISING INCIDENCE OF CARDIOVASCULAR AND CORONARY ARTERY DISEASES 25
4.2.2 GROWING AWARENESS, EXPENDITURE, AND DEPENDENCE ON ANTICOAGULANTS 25
4.3 RESTRAINTS 26
4.3.1 STRINGENT REGULATORY NORMS 26
4.4 OPPORTUNITIES 27
4.4.1 INCREASING PATIENT POPULATION AND PATENT EXPIRY TO SUPPORT NEW PRODUCT LAUNCH 27
5 MARKET FACTOR ANALYSIS 28
5.1 VALUE CHAIN ANALYSIS 28
5.1.1 R&D 29
5.1.2 MANUFACTURING 29
5.1.3 DISTRIBUTION AND SALES 29
5.1.4 POST-SALES MONITORING 29
5.2 PORTER’S FIVE FORCES MODEL 29
5.2.1 BARGAINING POWER OF SUPPLIERS 30
5.2.2 BARGAINING POWER OF BUYERS 30
5.2.3 THREAT OF NEW ENTRANTS 30
5.2.4 THREAT OF SUBSTITUTES 31
5.2.5 INTENSITY OF RIVALRY 31
5.2.6 US AND GLOBAL NUMBER OF PATIENTS ON ANTICOAGULANTS (2019), IN MILLION 31
5.3 IMPACT OF COVID-19 ON THE ANTICOAGULATION MARKET 32
5.3.1 OVERVIEW 32
5.3.2 IMPACT ON SUPPLY CHAIN 32
5.3.3 IMPACT ON DEMAND FOR ANTICOAGULATION DRUGS 32
5.3.4 EFFECT 0F ANTICOAGULATION ON COVID-19 PATIENTS 33
5.4 PATENT EXPIRATION OF ALL KEY DOACS 34
5.4.1 INTRODUCTION 34
6 GLOBAL ANTICOAGULATION MARKET, BY DRUG CLASS 35
6.1 OVERVIEW 35
6.2 DOACS 36
6.3 WARFARIN 38
6.4 OTHER VITAMIN K 39
6.5 LMWH 40
7 GLOBAL ANTICOAGULATION MARKET, BY DISEASE INDICATION 41
7.1 OVERVIEW 41
7.2 HEART ATTACK 42
7.3 STROKE 42
7.4 DVT/PE 43
7.5 MHV 43
7.6 OTHERS 44
8 GLOBAL ANTICOAGULATION MARKET, BY ROA 45
8.1 OVERVIEW 45
8.2 ORAL 46
8.3 INJECTABLE 46
8.4 OTHERS 47
9 GLOBAL ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL 48
9.1 OVERVIEW 48
9.2 RETAIL PHARMACY 49
9.3 HOSPITAL PHARMACIES 49
9.4 ONLINE PHARMACIES 50
10 GLOBAL ANTICOAGULATION MARKET, BY REGION 51
10.1 OVERVIEW 51
10.2 NORTH AMERICA 53
10.2.1 US 55
10.2.2 CANADA 57
10.3 EUROPE 59
10.3.1 GERMANY 61
10.3.2 UK 63
10.3.3 FRANCE 65
10.3.4 ITALY 67
10.3.5 SPAIN 69
10.3.6 REST OF EUROPE 71
10.4 ASIA-PACIFIC 73
10.5 REST OF THE WORLD 86
11 COMPETITIVE LANDSCAPE 94
11.1 OVERVIEW 94
11.2 COMPETITIVE BENCHMARKING 95
11.3 GLOBAL ANTICOAGULATION MARKET: COMPANY RANKING 96
11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 97
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 97
11.5.1 NEW PRODUCT LAUNCHES 97
11.6 FINANCIAL MATRIX 98
12 COMPANY PROFILES 99
12.1 PFIZER, INC. 99
12.1.1 COMPANY OVERVIEW 99
12.1.2 FINANCIAL OVERVIEW 100
12.1.3 PRODUCTS/SERVICES OFFERED 100
12.1.4 KEY DEVELOPMENTS 100
12.1.5 SWOT ANALYSIS 101
12.1.6 KEY STRATEGIES 101
12.2 SANOFI 102
12.2.1 COMPANY OVERVIEW 102
12.2.2 FINANCIAL OVERVIEW 102
12.2.3 PRODUCTS/SERVICES OFFERED 103
12.2.4 KEY DEVELOPMENTS 103
12.2.5 SWOT ANALYSIS 103
12.2.6 KEY STRATEGIES 103
12.3 JOHNSON & JOHNSON SERVICES INC. 104
12.3.1 COMPANY OVERVIEW 104
12.3.2 FINANCIAL OVERVIEW 104
12.3.3 PRODUCTS/SERVICES OFFERED 105
12.3.4 KEY DEVELOPMENTS 105
12.3.5 SWOT ANALYSIS 105
12.3.6 KEY STRATEGIES 105
12.4 GLAXOSMITHKLINE PLC 106
12.4.1 COMPANY OVERVIEW 106
12.4.2 FINANCIAL OVERVIEW 106
12.4.3 PRODUCTS/SERVICES OFFERED 107
12.4.4 KEY DEVELOPMENTS 107
12.4.5 SWOT ANALYSIS 107
12.4.6 KEY STRATEGIES 107
12.5 DAIICHI SANKYO COMPANY, LIMITED 108
12.5.1 COMPANY OVERVIEWS 108
12.5.2 FINANCIAL OVERVIEW 108
12.5.3 PRODUCTS/SERVICES OFFERED 109
12.5.4 KEY DEVELOPMENTS 109
12.5.5 SWOT ANALYSIS 109
12.5.6 KEY STRATEGIES 110
12.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 111
12.6.1 COMPANY OVERVIEW 111
12.6.2 FINANCIAL OVERVIEW 112
12.6.3 PRODUCTS/SERVICES OFFERED 112
12.6.4 KEY DEVELOPMENTS 113
12.6.5 SWOT ANALYSIS 113
12.6.6 KEY STRATEGIES 113
12.7 BRISTOL-MYERS SQUIBB COMPANY 114
12.7.1 COMPANY OVERVIEW 114
12.7.2 FINANCIAL OVERVIEW 114
12.7.3 PRODUCTS/SERVICES OFFERED 115
12.7.4 KEY DEVELOPMENTS 115
12.7.5 SWOT ANALYSIS 115
12.7.6 KEY STRATEGIES 115
12.8 PORTOLA PHARMACEUTICALS, INC 116
12.8.1 COMPANY OVERVIEW 116
12.8.2 FINANCIAL OVERVIEW 116
12.8.3 PRODUCTS/SERVICES OFFERED 117
12.8.4 KEY DEVELOPMENTS 117
12.8.5 SWOT ANALYSIS 118
12.8.6 KEY STRATEGIES 118
12.9 NOVARTIS AG 119
12.9.1 COMPANY OVERVIEW 119
12.9.2 FINANCIAL OVERVIEW 119
12.9.3 PRODUCTS/SERVICES OFFERED 120
12.9.4 KEY DEVELOPMENTS 120
12.9.5 SWOT ANALYSIS 120
12.9.6 KEY STRATEGIES 120
12.10 F. HOFFMANN-LA ROCHE LTD 121
12.10.1 COMPANY OVERVIEW 121
12.10.2 FINANCIAL OVERVIEW 122
12.10.3 PRODUCTS/SERVICES OFFERED 122
12.10.4 KEY DEVELOPMENTS 122
12.10.5 SWOT ANALYSIS 123
12.10.6 KEY STRATEGIES 123
13 APPENDIX 124
13.1 REFERENCES 124
13.2 RELATED REPORTS 124
